In the News

For media inquiries, please contact cci@ccf.org

03/09/2021

OncoSynergy Announces First Patient Treated in First-in-Human Clinical Trial of OS2966 in Recurrent Glioblastoma

OncoSynergy, Inc., a physician-founded oncology company committed to advancing therapeutics to address dire unmet medical needs, announced today that the first patient was treated in the Company's First-in-Human Phase 1 clinical trial evaluating OS2966 for the treatment of recurrent glioblastoma at Moffitt Cancer Center in Tampa, Florida.  OS2966 is a first-in-class immunotherapy, and the first ever anti-CD29 (beta 1 integrin) therapeutic to reach human trials. 


02/09/2021

Cleveland Diagnostics Raises $19.4M

Cleveland Diagnostics, Inc., a clinical-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, announced today that it has closed a Series D round of $17.4 million. The round was led by LYFE Capital, with participation from existing investors including Cleveland Clinic and others. Following the close of the round, the company received a term sheet for a $2M convertible note, expected to close shortly. Funds raised will be used to expand commercialization of IsoPSA—the company’s first diagnostic test, designed to enhance early detection of prostate cancer—as well as to expand internal infrastructure and operations to support platform development for other tests, including breast and lung cancer.


02/09/2021

Eurofins Viracor, Cleveland Clinic Sign License Deal for Kidney Transplant Rejection Biomarker Test

Diagnostics company Eurofins Viracor said on Monday that it has signed a licensing agreement with the Cleveland Clinic for exclusive rights to a urine biomarker test for detecting rejection in kidney transplant patients.


02/09/2021

Taysha Gene Therapies Announces Collaborations to Advance Next-Generation Mini-Gene Payloads for AAV Gene Therapies for the Treatment of Genetic Epilepsies and Additional CNS Disorders

Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced multi-year collaborations with Cleveland Clinic and UT Southwestern Gene Therapy Program (UTSW) to advance next-generation mini-gene payloads for AAV gene therapies for the treatment of genetic epilepsies and additional CNS disorders.


02/08/2021

Eurofins Viracor, Cleveland Clinic Sign License Deal for Kidney Transplant Rejection Biomarker Test

Diagnostics company Eurofins Viracor said on Monday that it has signed a licensing agreement with the Cleveland Clinic for exclusive rights to a urine biomarker test for detecting rejection in kidney transplant patients.


01/29/2021

Olympus to Acquire Quest Photonic Devices B.V. to Bolster Surgical Endoscopy Capabilities

Olympus Corporation (TSE: 7733) today announced that it has entered into an agreement to acquire Quest Photonic Devices B.V. (Quest; CEO: Richard Meester) for up to EUR50 million including milestone payments to strengthen its surgical endoscopy capabilities.


01/29/2021

Cleveland Clinic receives $6.7 million NIH grant to study high-intensity exercise as Alzheimer's prevention

Cleveland Clinic receives $6.7 million NIH grant to study high-intensity exercise as Alzheimer's preventionThe five-year study will assess the effect of home-based indoor cycling in slowing disease progression in healthy older people at high genetic risk for developing Alzheimer's disease. 


01/25/2021

Through a $500 Million Partnership with the State of Ohio, JobsOhio and Ohio Development Services Agency, Cleveland Clinic Forms Global Center for Pathogen Research & Human Health

As part of the new Cleveland Innovation District announced today by State of Ohio Governor Mike DeWine, Lieutenant Governor Jon Husted, JobsOhio and Ohio Development Services Agency, Cleveland Clinic will significantly expand its global commitment to infectious disease research and translational programs to form the Global Center for Pathogen Research & Human Health.


01/18/2021

First Case Completed in Feasibility Study of Non-Radiation-Based EVAR Navigation Platform

In December, Cleveland Clinic vascular surgeons successfully completed the first surgical case in the MOTION clinical trial of a new non-radiation-based surgical navigation platform for endovascular aortic interventions.


01/13/2021

Publication of a Health Economic Analysis Demonstrates IsoPSA® Significantly Reduces Unnecessary Prostate Cancer Biopsies and Costs

CLEVELAND--()--Cleveland Diagnostics, Inc., a clinical-stage biotechnology company focused on the development of next-generation diagnostic tests for early detection of cancers, announced today the publication of a health economic analysis in Urology Practice. The publication demonstrates the cost effectiveness and economic utility of Cleveland Diagnostics’ IsoPSA test for the detection of clinically significant prostate cancer.


   <  2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10 - 11  >   

Get In Touch With Us